Early Efficacy & Safety Data Planned for XanADu Trial
Filed with ASX · · 2 pages · English
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- Placement Fully Funds Completion of XanADu Alzheimers Trial
- R&D Rebate Received Totalling $1.22 Million
- Quarterly Update & Appendix 4C
- Final Major Market Patent Granted for Xanamem
- First Patient Completes Landmark Alzheimers Disease Trial
Later from Actinogen Medical
- Prospectus
- December 2017 Quarterly Report
- New Data Supports Cortisol Hypothesis
- Strong Recruitment Progress in Alzheimers Trial
- Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical